Introduction: Diffuse large B cell lymphoma (DLBCL), the most common lymphoma diagnosis, has heterogeneous biology and prognosis. Frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), used regardless of subtype, cures ∼60%, but relapsed/refractory patients have persistently poor prognosis. Efforts to improve frontline and establish subtype-targeted therapy have largely failed.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile